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Abstract 
Background 
Frailty is a multidimensional geriatric syndrome characterised by a state of increased 
vulnerability to disease. Its causes are unclear, limiting opportunities for intervention. Age 
related changes to the immune-endocrine axis are implicated. This study investigated the 
associations between the immune-endocrine axis and frailty as well as mortality ten years 
later among men and women aged 65 to 70 years.  
Methods 
We studied 254 participants of the Hertfordshire Ageing Study at baseline and 10 year follow 
up. At baseline (1994/5) they completed a health questionnaire and had collection of blood 
samples for immune-endocrine analysis. At follow up (2003/5), frailty was characterised and 
mortality ascertained.  
Findings 
Higher baseline levels of white cell count (WCC), neutrophils, monocytes, lymphocytes, 
ESR, T4 and lower levels of DHEAS and higher cortisol:DHEAS ratio were all significantly 
associated with increased odds of frailty at follow-up. Higher baseline levels of ESR, 
neutrophils, monocytes and IL-1β were all associated with increased likelihood of all-cause 
mortality during the follow-up period. Baseline WCC and cortisol:DHEAS clearly 
discriminated between individuals who went on to be frail at follow-up.    
Interpretation 
We present the first evidence that immune-endocrine biomarkers are associated with the 
likelihood of frailty as well as mortality over a 10 year period. This augments our 
understanding of the aetiology of frailty and a suggests a screening programme at ages 60-
70 years could help to identify individuals who are at high risk of becoming frail and who 
would benefit from early, targeted intervention, for example with DHEA supplementation or 
anti-inflammatory strategies.  Progress towards the prevention of frailty would bring major 
health and socioeconomic benefits at the individual and the population level.  
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Introduction 
 
Frailty is a multidimensional geriatric syndrome (1); it may be described as a state of 
increased vulnerability which results from decreased physiological reserves, multi-system 
dysregulation and limited capacity to maintain homeostasis (2). Frailty is of increasing global 
importance, impacting on all forms of adult healthcare as well as socioeconomic policy. A 
person who is frail is less likely to be living independently at home and people who are frail 
have an increased likelihood of morbidity and mortality (3;4). Frailty also has predictive 
validity for adverse health outcomes including falls, disability and receipt of hospital care 
(4;5). A major healthcare challenge of the 21st century is to identify people at risk of 
becoming frail and intervene early.  
 
The Fried criteria (4), the most widely implemented objective approach to the classification of 
frailty, define frailty on the basis of weight loss, weakness, exhaustion, slowness and low 
activity. Prevalence estimates were recently reported as 8·5% for women and 4·1% for men 
among community dwelling people aged 64 to 74 years (6). The numbers of frail older 
people will increase as populations age, particularly as numbers at the oldest ages are 
increasing the fastest.  
 
Age-related changes in the immune-endocrine axis are implicated in a wide range of disease 
processes in older people, causing significant morbidity and mortality (7) . For example, 
white blood cells, are positively associated with cardiovascular disease, cancer and all-
cause mortality (8). Levels of dehydroepiandosterone-sulphate (DHEAS) decline with age 
and these too are associated with increased morbidity including cardiovascular disease (9), 
osteoporosis (10) and all cause mortality (11). Relationships between low thyroid function 
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and lifespan in older people have also been noted and raised serum free T4 is associated 
with increased mortality in the oldest old (12).  
 
These changes are also implicated in the frailty syndrome. Cross-sectional associations 
have been demonstrated with C-reactive protein (CRP), interleukin (IL)-6, total white-blood 
cell counts, neutrophils, monocytes, insulin-like growth factor-1 and DHEAS (13-17). 
However causality cannot be determined in cross-sectional studies and to date, only a small 
number of studies have examined longitudinal associations between inflammation and frailty 
(18;19). Few other biomarkers associated with the onset of frailty have yet been identified.  
 
The objective of the current study was to investigate the associations between biomarkers of 
the immune-endocrine axis and frailty as well as all-cause mortality ten years later among 
community dwelling men and women aged 65 to 70 years. 
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Methods 
The Hertfordshire Ageing Study (HAS) has been described previously (20). In brief, 717 men 
and women who were born in Hertfordshire, UK between 1920 and 1930 attended a home 
interview and clinic in 1994/5 where a wide range of markers of ageing were characterised. 
In 2003/5, a ten year follow-up was conducted; 359 men and women participated in a home 
interview of whom 254 attended a clinic at which Fried frailty was assessed (20). All-cause 
mortality was ascertained between the two phases.  
 
At the 1994/5 baseline HAS home interview a trained research nurse ascertained smoking 
habit, alcohol intake, self-reported walking speed, medications, and current or most recent 
full-time occupation and husband’s occupation for ever-married women. At the 1994/5 
baseline HAS clinic, height and weight were measured. Grip strength was measured using a 
Jamar hand grip dynamometer. Venous blood was collected for laboratory automated 
haemoglobin, white cell counts, erythrocyte sedimentation rate (ESR), albumin, thyroid 
stimulating hormone (TSH), free T4 (T4), testosterone and sex-hormone binding globulin 
(SHBG) and serum stored at -80°C.  
 
Serological Analysis 
The serum free cytokines IL-1β, IL-6, IL-10 and TNF-α were simultaneously measured using 
commercially available multiplex luminometry whilst C-reactive protein was measured using 
singleplex luminometry (Invitrogen, UK). Detection of serum cortisol and DHEAS was 
completed using commercially available enzyme-linked immunosorbent assay kits, (IBL 
International, Germany) (REF). 
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Frailty was assessed at the 2003/5 follow-up. The Fried criteria define frailty as presence of 
three or more of the following: unintentional weight loss (greater than 10lb over the past 
year), weakness, self-reported exhaustion, slow walking speed and low physical activity (3). 
These were operationalised as previously in the Hertfordshire Cohort Study (4) and as 
follows: weakness was defined as a maximum grip strength of ≤30kg for men and ≤20kg for 
women (21); exhaustion was identified if the participant felt that everything they did was an 
effort for either moderate amounts or most of the time in the past week; slow walking speed 
was defined as a 3m walk time in the slowest fifth of the HAS sex-specific distribution (≥4·04 
seconds for men and  ≥4·54 seconds for women); and low physical activity was identified if 
the participant had a short-form 36 (SF-36) physical functioning score in the bottom fifth of 
the HAS sex-specific distribution (<45 for men and <33 for women).  
 
Intra- and inter-observer studies were carried out during the fieldwork. The HAS had ethical 
approval from the Hertfordshire and Bedfordshire Local Research Ethics Committee and all 
participants gave written informed consent. 
 
Statistical methods 
 
Positively skewed biomarkers were loge transformed to normal distributions as necessary. 
Weight and height were positively correlated (men r=0·53,p<0·001; women r=0·31,p<0·001); 
to avoid multicolinearity problems, a standardised residual of weight adjusted for height was 
derived. Follow-up time was calculated as time elapsed in decimal years between the HAS 
1994/5 baseline and 2003/5 follow-up clinics. Pearson’s correlation coefficients and principal 
components analysis were used to explore the inter-relationships between the immune-
endocrine biomarkers. Cox’s proportional hazards models and logistic regression models 
were used to analyse the associations between the 1994/5 baseline panel of biomarkers and 
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all-cause mortality between data collection points and Fried frailty at the 2003/5 follow-up 
respectively. Analyses were conducted with and without adjustment for the potential 
confounding effects of gender, follow-up duration (for logistic models for frailty only), and 
1994/5 baseline age, height, weight for height, smoking status, alcohol consumption, social 
class in adulthood, walking speed, and number of systems medicated. A 5% significance 
level was principally used to identify statistically significant associations but a Bonferroni 
correction was also applied to enable identification of significant associations after allowance 
for multiple comparisons. Receiver-operating characteristic (ROC) curves were used to 
explore the ability of the 1994/5 baseline biomarkers to discriminate between frailty status at 
follow-up in 2003/5. Data were principally analysed for men and women combined but 
analyses were repeated for men and women separately. All analyses were conducted using 
Stata 11 (Stata Statistical Software, StataCorp, 2009).    
 
Results 
411 men and 306 women participated in the 1994/5 baseline clinic; 81 men (19·7%) and 40 
women (13·1%) had died by the time of the 2003/5 follow-up (hazard ratio [HR] for men 
compared with women 1·51, 95% confidence interval [95%CI] 1·03, 2·21, p=0·03; total 
person years of follow-up 5,971).   
 
Table 1 shows the baseline summary characteristics of the 153 men and 101 women who 
participated in the 1994/5 baseline clinic and who were also assessed for Fried frailty status 
at 2003/5 follow-up. The average age at the 1994/5 baseline clinic was 66·9 years for men 
and 67·3 years for women. The median follow-up time was 10·4 years for men and 9·9 years 
for women. At the 2003/5 follow-up the prevalence of Fried frailty was 5·2% for men and 
11·9% for women (p=0·05 for gender difference).  Immune biomarkers were strongly inter-
correlated: the pairwise correlation coefficients between white cell count and each of 
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neutrophils, monocytes and lymphocytes ranged from 0·58 to 0·91, all p<0·0001. In addition, 
neutrophils and monocytes were strongly correlated with one another (r=0·58, p<0·0001) 
and CRP was correlated with each of white cell count, neutrophils, monocytes and ESR 
(correlation coefficients ranged from 0·33 to 0·37, all p<0·0001). However, the endocrine 
markers cortisol and DHEAs were independent of one another (r=0·01, p=0·90) and of all 
the other biomarkers considered in Table 1 (correlations ranged from 0·02 to 0·15, p≥0·03 
for all) with the exception of the ratio of cortisol to DHEAs of which they are a component.  A 
principal components analysis for the biomarkers in table 1 confirmed these patterns of 
association: the first principal component accounted for 19% of the variation in the data and   
was a weighted average of white cell count, neutrophils, monocytes, lymphocytes and CRP; 
the second component accounted for 12% of the variation in the data and was a contrast 
between cortisol and DHEAs. 
 
Table 2 presents the associations between the panel of biomarkers as measured for 717 
men and women at the 1994/5 clinic and all-cause mortality between HAS follow-ups for 
men and women combined. In unadjusted analyses, an SD increase in levels of ESR (HR 
[95%CI] 1·33 [1·11,1·58], p=0·002), neutrophils (HR[95% CI] 1·33 [1·11,1·59], p=0·002), 
monocytes (HR[95% CI] 1·19 [1·00,1·43], p=0·05) and IL-1β (HR[95% CI] 1·17 [1·00,1·36], 
p=0·04) were all associated with increased likelihood of mortality between data collection 
points. The associations between ESR and neutrophils and mortality were also significant 
after Bonferroni correction (p<0·003). The results were unaltered by adjustment for gender 
and age at 1994/5 baseline (table 2). However, the associations between monocytes, IL-1β 
and mortality were attenuated by also adjusting for height, weight for height, smoking, 
alcohol, social class, walking speed, and number of systems medicated, all as ascertained in 
1994/5 baseline.  
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Table 3 presents the associations between the panel of biomarkers as measured at the 
1994/5 baseline and Fried frailty status at 2003/5 follow-up for men and women combined. In 
unadjusted analyses, an SD increase in levels of white cell count (odds ratio OR[95%CI] 
2·51 [1·49,4·24], p=0·001), ESR (OR[95%CI] 2·23 [1·28,3·88], p=0·005), neutrophils 
(OR[95% CI] 2·17 [1·29,3·65], p=0·004), monocytes (OR[95% CI] 3·22 [1·80,5·74], 
p<0·001), lymphocytes (OR[95% CI] 2·00 [1·23,3·25], p=0·005), T4 (OR[95% CI] 1·86 
[1·11,3·13], p=0·02) and ratio of cortisol to DHEAS (OR[95%CI] 1·78 [1·17,2·72], p=0·007), 
and an SD decrease in  levels of DHEAS (OR[95% CI] 2·04 [1·30,3·23] p=0·002),were all 
associated with increased odds of frailty at 2003/5 follow-up. The associations between 
white cell count, monocytes and DHEAS and frailty were also significant after Bonferroni 
correction (p<0·003). The results were unaltered by adjustment for gender, age and duration 
of follow-up (table 3). However, the associations between ESR (p=0·05) and T4 (p=0·07) 
were attenuated by also adjusting for height, weight for height, smoking, alcohol, social class 
and walking speed. The associations between white cell count, monocytes, lymphocytes, 
DHEAS, and ratio of cortisol to DHEAS with frailty were little altered by additionally adjusting 
for number of systems medicated at the 1994/5 baseline as a marker of co-morbidity. The 
prevalence of frailty according to thirds of the distribution of white cell count, neutrophils, 
monocytes, lymphocytes, DHEAS, and ratio of cortisol to DHEAS is shown in Figure 1.  
 
Receiver operating characteristic (ROC) curves were used to explore the ability of white cell 
count (an immune marker) and the ratio of cortisol to DHEAS (an endocrine marker) at the 
1994/5 baseline to discriminate between frail and non-frail individuals at the 2003/5 follow-
up. The ROC areas under the curve were 0·70 (95%CI 0·55, 0·84) for white cell count and 
0·72 (95%CI 0·59, 0·86) for ratio of cortisol to DHEAS; both areas under the curve are 
suggestive of fair-good discrimination between frail and non-frail individuals. The optimal 
categorisations for discrimination between frail and non-frail individuals were ≥6x109/L 
versus <6x109/L for white cell count (frailty prevalence 12·1% versus 4·6% respectively), and 
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≥0·172 versus <0·172 for ratio of cortisol to DHEAS (frailty prevalence 12·6% versus 3·8%). 
Further discrimination was achieved by combining the categorisations of white cell count and 
ratio of cortisol to DHEAS; the prevalence of frailty at 2003/5 follow-up among individuals 
who had a white cell count <6x109/L  and a ratio of cortisol to DHEAS <0·172 at 1994/5 
baseline was only 2·0% in contrast with a prevalence of 8·0% among individuals who had 
only one of white cell count ≥6x109/L or ratio ≥0·172, and a frailty prevalence of 17·1% 
among individuals with white cell count ≥6x109/L and ratio of cortisol to DHEAS ≥0·172. 
 
Results were similar for men and women analysed separately (data not shown), but the 
strength of statistical significance was lower for all associations owing to limited power from 
smaller sample sizes.   
 
Discussion 
 
We have shown that higher baseline levels of total WCC, neutrophils, monocytes, 
lymphocytes, ESR and free T4, and lower levels of DHEAS as well as higher ratios of 
cortisol to DHEAS were all associated with an increased likelihood of being frail at ten year 
follow-up in a cohort of community dwelling older people. Higher baseline levels of ESR, 
neutrophils, monocytes and IL-1β were associated with increased likelihood of all-cause 
mortality across the ten years.  
 
We have also demonstrated that a single baseline marker of the immune axis (WCC), 
combined with a baseline marker of the endocrine axis (cortisol:dheas), clearly discriminated 
between individuals who went on to be frail at ten year follow-up . If validated in other 
populations, our results suggest that a screening programme at ages 60-70 years could help 
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to identify individuals who are at high risk of becoming frail and who would benefit from early, 
targeted intervention. This might include comprehensive geriatric assessment, medical, 
nutritional and exercise treatments (22;23). Pharmacological interventions are also being 
trialled (13;24). Furthermore, these biomarkers are simple, inexpensive and routinely used in 
clinical practice; they may be combined with other markers (e.g. grip strength, sarcopenia) to 
increase accuracy and generate a functional predictive tool of clinical value. This has 
implications in-terms of healthcare planning and policy making and high potential of 
significant social, economic and well-being benefits at both individual and global population 
levels.   
 
These findings complement and add to cross-sectional studies by Leng and colleagues who 
showed that high neutrophil and monocytes counts were associated with frailty in disabled 
older women (15) and also Voznesensky and colleagues who demonstrated associations 
with DHEAS in community dwelling older people (14). This is the first study to show 
longitudinal associations with frailty across both the immune and endocrine axis, suggesting 
that the age associated changes to the cellular immune system and hypothalamic-pituitary-
adrenal (HPA) axis are central to the rate of development of age-associated diseases and, 
as a consequence, to frailty and mortality.  
 
White blood cells are important co-ordinators of inflammation; the age associated decline of 
the immune system, immunesenescence, is well documented (25). These changes 
contribute to inflamm-aging, a progressive increase in pro-inflammatory status with age (26), 
and potentially an important mechanism explaining the association of white cells with 
prevalent frailty and mortality. Associations between specific pro-inflammatory cytokines or 
CRP and frailty have not been shown in this study; this may reflect the complexities of 
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inflammation which involves an inflammatory milieu of multiple proteins rather than a specific 
inflammatory protein.  
 
Both cortisol and the DHEAS are outputs of the HPA axis; cortisol has mainly 
immunosuppressive actions while DHEAS is immune enhancing (25). With ageing there is 
increasing imbalance between the two hormones, due to reducing DHEAS levels from age 
30 years onwards (adrenopause), and relatively stable cortisol levels (27). Raised levels of 
thyroid hormone are thought to further modulate the HPA axis through central changes in 
sensitivity to corticotrophin releasing hormone (28). These changes are believed to 
contribute to the process of immunesenescence (29). Furthermore, cortisol and DHEAS 
have direct effects on frailty via interaction with anabolic and catabolic pathways within 
myocytes. Importantly, this ratio can be manipulated via pharmacological supplementation 
with DHEA to raise serum DHEAS levels. A recent randomised controlled trail by Kenny and 
colleagues demonstrated that DHEA supplementation improved sarcopenia in already frail 
women involved in gentle exercise when compared to placebo (24). 
 
Our study has some limitations. Firstly, we cannot completely exclude the effects of co-
existing sub-clinical infections at the time of immune-endocrine analysis. However, 
participants were presumed fit and able to attend clinic appointments for data collection and 
results were screened prior to analysis for patterns suggestive of acute infection or 
haematological malignancy and four results removed from the data set. Secondly, study 
participants were lost to follow-up between the 1994/5 baseline and 2003/5 follow-up clinics 
due to a variety of reasons (including mortality, loss to follow-up, refusal to participate) and 
we have previously shown that a healthy participant effect is, unsurprisingly, evident in HAS 
(20). In the current study, the 153 men who went on to have frailty classified at 2003/5 HAS 
follow-up were significantly (p<0·05) younger, less likely to be current smokers, were of 
higher social class, and had lower white cell count, ESR, neutrophil, monocytes, T4, IL-6 and 
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CRP levels at the 1994/5 clinic than the 258 men who only participated in the 1994/5 
baseline study. Selection effects were less evident for women; the 101 women who went on 
to have frailty classified at 2003/5 HAS follow-up were significantly (p<0·05) less likely to be 
current smokers and had lower neutrophil levels at the 1994/5 clinic than the 205 women 
who only participated in the 1994/5 study. These selection effects have the potential to bias 
our results. However, our analyses were internal to the HAS sample; bias would only be 
introduced if the associations between biomarkers and frailty were systematically different 
among those who participated in our study, and those who did not; this seems unlikely. 
Finally, there are numerous candidate biomarkers within the immune-endocrine axis that we 
did not analyse and there is scope to widen this biomarker battery. However this may add 
unnecessary complexity and we specifically chose readily available biomarkers to facilitate 
easy translation into the clinical environment. 
 
In conclusion, we present the first evidence that immune-endocrine biomarkers can predict 
the likelihood of frailty as well as mortality over a 10 year period. This augments our 
understanding of the aetiology of frailty and suggests the potential for screening and early 
identification and intervention in those at high risk. Progress towards the prevention of frailty 
would bring major health and socioeconomic benefits both at the individual and the 
population level. Further work is needed to replicate these findings in other studies and to 
elucidate the underlying mechanisms to develop the necessary evidence base for successful 
intervention strategies.  
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Table 1. Baseline (1994/5) characteristics of  participants in the 2003/5 HAS follow-up 
Mean (SD) Men (n=153) Women (n=101) 
Age (years) 66·9 (2·2) 67·3 (2·1) 
Height (cm) 172·6 (6·3) 159·8 (5·1) 
Weight (kg) 80·4 (12·2) 69·2 (10·6) 
Current smokera 19 (12·4) 9 (8·9) 
Moderate or higher weekly alcohol intakea,b  40 (26·1) 9 (8·9) 
Non-manual social classa,c 73 (48·3) 43 (43·4) 
Fairly brisk or fast walking speeda 42 (27·5) 26 (25·7) 
Number of systems medicatedd 1 (0,2) 1 (0,2) 
White cell count (x109/L) d 5·5 (4·8, 6·6) 5·5 (4·7, 6·5) 
ESR (mm/hr)d 6 (4,10) 14 (8,20) 
Neutrophils (x109/L) d 3·4 (2·8,4·0) 3·2 (2·5,4·0) 
Monocytes (x109/L) d 0·4 (0·3,0·5) 0·3 (0·3,0·4) 
Lymphocytes (x109/L) d 1·6 (1·3, 2·0) 1·7 (1·4,2·1) 
Albumin (g/L) 42·7 (2·0) 42·3 (2·0) 
SHBG (nmol/L) d 36·3 (27·9,48·3) 51·2 (34·2,79·2) 
Testosterone  (nmol/L) d 16·3 (11·1,20·3) No data 
Haemoglobin (g/L) 14·5 (1·0) 13·5 (0·9) 
TSH (mu/L) d 1·7 (1·2,2·3) 2·1 (1·5,3·3) 
T4 (pmol/L) d 14·2 (13·2,15·6) 13·7 (12·6,15·3) 
IL-1B (pg/ml) d 11·3 (5·6,17·7) 18·3 (11·7,26·2) 
IL-6 (pg/ml) d 1·2 (0·2,2·0) 0·9 (0·4,2·0) 
IL-10 (pg/ml)d 2·3 (2·5,4·7) 1·9 (0·3,2·1) 
CRP (mg/l) d 1·9 (0·9,4·0) 3·1 (1·1,5·6) 
DHEAS (nmol/l) d 2181 (1734,2888) 1495 (797,2261) 
Cortisol (nmol/l) d 308 (235,385) 274 (210,349) 
Ratio of Cortisol to DHEASd 0·12 (0·09, 0·17) 0·19 (0·10, 0·38) 
Follow-up time (years)d 10·4 (10·2,10·5) 9·9 (9·8,10·1) 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aNumber and percentage   b Defined as weekly alcohol consumption of ≥11 units for men and ≥8 units for women  
Fried frailtya,e 8 (5·2) 12 (11·9) 
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c Defined as classes I, II and IIINM of the 1990 OPCS coding of social class. Social class was identified on the basis of own 
current/most recent full-time occupation for men and never-married women, and from husband’s occupation for ever-married 
women  d Variable was positively skewed; median and inter-quartile range presented  eAssessed at the 2003/5 follow-up 
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Table 2. Associations between 1994/5 biomarkers and all-cause mortality between HAS follow-ups for men and women combined  
Biomarker N HRa 95%CI p HRb 95%CI p HRc 95%CI p HRd 95%CI p 
White cell count (x109/L) 697 1·18 (0·98,1·42) 0·081 1·17 (0·98,1·41) 0·089 1·15 (0·96,1·39) 0·133 1·15 (0·95,1·38) 0·155 
ESR (mm/hr) 708 1·33 (1·11,1·58) 0·002 1·31 (1·10,1·56) 0·002 1·22 (1·01,1·48) 0·037 1·22 (1·01,1·47) 0·041 
Neutrophils (x109/L) 708 1·33 (1·11,1·59) 0·002 1·31 (1·09,1·57) 0·003 1·21 (1·00,1·47) 0·046 1·21 (1·00,1·46) 0·054 
Monocytes (x109/L) 708 1·19 (1·00,1·43) 0·054 1·19 (0·99,1·42) 0·064 1·13 (0·93,1·36) 0·214 1·12 (0·93,1·35) 0·235 
Lymphocytes (x109/L) 708 1·10 (0·91,1·32) 0·319 1·11 (0·93,1·33) 0·261 1·06 (0·88,1·28) 0·560 1·07 (0·88,1·29) 0·490 
Albumin (g/L) 708 0·93 (0·77,1·11) 0·401 0·92 (0·77,1·11) 0·386 0·94 (0·78,1·12) 0·480 0·94 (0·79,1·12) 0·488 
SHBG (nmol/L) 689 0·93 (0·77,1·11) 0·411 0·93 (0·78,1·11) 0·433 0·95 (0·79,1·14) 0·587 0·98 (0·82,1·18) 0·856 
Testosterone (nmol/L)e 711 1·18 (0·98,1·42) 0·075 1·16 (0·97,1·40) 0·108 1·15 (0·94,1·40) 0·172 1·14 (0·94,1·39) 0·193 
Haemoglobin (g/L) 408 0·98 (0·78,1·24) 0·894 0·98 (0·78,1·24) 0·888 0·99 (0·76,1·28) 0·937 1·00 (0·77,1·30) 0·989 
TSH (mu/L) 708 0·94 (0·78,1·13) 0·521 0·96 (0·80,1·15) 0·655 0·96 (0·80,1·15) 0·643 0·97 (0·81,1·17) 0·783 
T4 (pmol/L) 696 0·95 (0·79,1·14) 0·609 0·96 (0·80,1·15) 0·664 1·00 (0·83,1·20) 0·979 1·00 (0·83,1·20) 0·987 
IL-1B (pg/ml) 705 1·17 (1·00,1·36) 0·044 1·18 (1·00,1·38) 0·045 1·16 (0·98,1·37) 0·085 1·14 (0·96,1·35) 0·149 
IL-6 (pg/ml) 504 0·97 (0·78,1·20) 0·760 0·98 (0·79,1·22) 0·857 0·96 (0·77,1·19) 0·703 0·96 (0·77,1·19) 0·706 
IL-10 (pg/ml) 439 1·09 (0·87,1·37) 0·431 1·09 (0·87,1·37) 0·459 1·02 (0·81,1·29) 0·846 1·02 (0·81,1·28) 0·882 
CRP (pg/ml) 537 0·95 (0·78,1·17) 0·655 0·95 (0·78,1·17) 0·647 0·98 (0·80,1·20) 0·834 0·98 (0·80,1·21) 0·875 
DHEAS (nmol/l) 673 1·18 (0·97,1·43) 0·091 1·19 (0·98,1·44) 0·083 1·12 (0·92,1·37) 0·262 1·10 (0·90,1·35) 0·354 
Cortisol (nmol/l) 692 1·08 (0·90,1·31) 0·409 1·08 (0·89,1·31) 0·426 1·09 (0·90,1·32) 0·395 1·08 (0·89,1·30) 0·430 
Ratio of cortisol:DHEAS 689 1·04 (0·86,1·26) 0·668 1·04 (0·86,1·25) 0·710 1·02 (0·84,1·24) 0·814 1·00 (0·82,1·21) 0·978 
N, number; HR, hazard ratio; CI, confidence interval; p, p-value 
aUnadjusted hazard ratio for mortality per SD (standard deviation) increase in biomarker. bHazard ratio adjusted for gender and baseline age 
cHazard ratio adjusted as in b and also for baseline height, weight for height, smoking, alcohol, social class and waking speed 
dHazard ratio adjusted as in c and also adjusted for baseline number of systems medicated as a marker of comorbidity    
e Based on data for men only  
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Table 3. Associations between 1994/5 biomarkers and Fried frailty status at 2003/5 follow-up for men and women combined  
Biomarker N ORa 95%CI p ORb 95%CI p ORc 95%CI p ORd 95%CI p 
White cell count (x109/L) 252 2·51  (1·49,4·24) 0·001 2·85 (1·60,5·07) <0·001 2·36  (1·24,4·51) 0·009 2·22 (1·14,4·33) 0·019 
ESR (mm/hr) 246 2·23 (1·28,3·88) 0·005 2·36 (1·29,4·30) 0·005 2·04 (0·99,4·21) 0·054 1·77 (0·85,3·65) 0·125 
Neutrophils (x109/L) 252 2·17 (1·29,3·65) 0·004 2·42 (1·37,4·25) 0·002 1·92 (1·05,3·52) 0·035 1·83 (0·96,3·52) 0·068 
Monocytes (x109/L) 252 3·22 (1·80,5·74) 0·000 4·11 (2·11,7·99) 0·000 4·23 (1·94,9·22) 0·000 3·88 (1·73,8·69) 0·001 
Lymphocytes (x109/L) 252 2·00 (1·23,3·25) 0·005 2·07 (1·26,3·40) 0·004 2·00 (1·14,3·53) 0·016 2·09 (1·15,3·79) 0·016 
Albumin (g/L) 251 0·70 (0·44,1·10) 0·123 0·66 (0·41,1·06) 0·085 0·59 (0·34,1·02) 0·058 0·48 (0·26,0·91) 0·024 
SHBG (nmol/L) 252 0·98 (0·63,1·52) 0·936 0·90 (0·57,1·40) 0·631 0·89 (0·51,1·55) 0·678 0·88 (0·48,1·61) 0·688 
Testosterone (nmol/L)e 151 1·54 (0·70,3·42) 0·285 1·06 (0·44,2·56) 0·892 4·06 (0·81,20·39) 0·089 5·42 (0·95,30·87) 0·057 
Haemoglobin (g/L) 252 0·84 (0·52,1·37) 0·495 0·84 (0·50,1·42) 0·522 0·69 (0·39,1·22) 0·203 0·82 (0·46,1·48) 0·515 
TSH (mu/L) 247 0·75 (0·48,1·17) 0·202 0·72 (0·45,1·16) 0·178 0·73 (0·42,1·26) 0·254 0·68 (0·39,1·20) 0·186 
T4 (pmol/L) 250 1·86 (1·11,3·13) 0·019 2·08 (1·16,3·72) 0·014 1·78 (0·95,3·32) 0·070 1·41 (0·74,2·67) 0·296 
IL-1B (pg/ml) 180 0·92 (0·51,1·63) 0·764 0·94 (0·51,1·72) 0·839 0·81 (0·43,1·54) 0·525 0·76 (0·40,1·44) 0·400 
IL-6 (pg/ml) 151 1·75 (0·87,3·54) 0·116 1·93 (0·90,4·16) 0·092 1·65 (0·73,3·76) 0·231 1·64 (0·71,3·76) 0·243 
IL-10 (pg/ml) 194 0·58 (0·29,1·14) 0·116 0·55 (0·26,1·18) 0·124 0·47 (0·17,1·29) 0·142 0·63 (0·22,1·83) 0·400 
CRP (pg/ml) 243 1·49 (0·88,2·51) 0·138 1·59 (0·88,2·86) 0·123 1·18 (0·58,2·42) 0·649 1·04 (0·49,2·18) 0·926 
DHEAS (nmol/l) 246 0·49 (0·31,0·77) 0·002 0·45 (0·27,0·74) 0·002 0·42 (0·23,0·74) 0·003 0·50 (0·27,0·91) 0·023 
Cortisol (nmol/l) 246 1·04 (0·63,1·74) 0·869 1·08 (0·63,1·84) 0·789 1·07 (0·59,1·94) 0·824 1·14 (0·60,2·16) 0·699 
Ratio of cortisol:DHEAS 246 1·78  (1·17,2·72) 0·007 2·03 (1·25,3·30) 0·004 2·02 (1·20,3·41) 0·008 1·79  (1·03,3·10) 0·037 
N, number; OR, odds ratio; CI, confidence interval; p, p-value 
aUnadjusted odds ratio for frailty per SD (standard deviation) increase in biomarker. bOdds ratio adjusted for gender, baseline age and follow-up duration 
cOdds ratio adjusted as in b and also for baseline height, weight for height, smoking, alcohol, social class and waking speed 
dOdds ratio adjusted as in c and also adjusted for baseline number of systems medicated as a marker of comorbidity    
e Based on data for men only  
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Figure 1. Prevalence of Fried frailty at 2003/5 follow-up for men and women combined 
according to biomarker distribution at 1994/5 baseline 
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Covering letter: 
 
Dear Dr Horton, 
 
 
Re: Immune-endocrine biomarkers of frailty and mortality: a ten year longitudinal 
study in community dwelling older people 
 
 
We would be grateful if you would consider the above research article for publication in your 
journal. We believe that it would be of considerable interest and relevance to your general 
and specialist international readership.  Frailty is a well known term and commonly used in 
everyday language. It is also frequently encountered in the day-to-day practice of clinicians 
looking after older people.  Its prevalence is increasing worldwide with population ageing and 
a decade has now passed since Linda Fried and colleagues first described the frailty 
phenotype. Despite this, studies of frailty are rarely reported in general medical journals.  
 
In this paper we present the novel and exciting epidemiological findings that immune-
endocrine biomarkers can predict the likelihood of frailty as well as mortality over a 10 year 
period. This is important because it augments our understanding of the aetiology of frailty 
and suggests the potential for a screening programme, early identification and intervention in 
individuals at high risk.  Progress towards the prevention of frailty would bring major health 
and socioeconomic benefits both at the individual and the population level. 
 
Thank you for considering our paper. We look forward to hearing from you. 
 
 
Yours sincerely 
 
 
 
 
D Baylis, D Bartlett, H Syddall, G Ntani, C Gale, C Cooper, J Lord, A Aihie Sayer 
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